How would you deploy the fixed ratio combination regimens in patients who had documented postprandial hyperglycemia? Would one combination offer an advantage over the other, based on pharmacokinetic properties of the GLP-1 RA?

How would you deploy the fixed ratio combination regimens in patients who had documented postprandial hyperglycemia? Would one combination offer an advantage over the other, based on pharmacokinetic properties of the GLP-1 RA?

How would you deploy the fixed ratio combination regimens in patients who had documented postprandial hyperglycemia? Would one combination offer an advantage over the other, based on pharmacokinetic properties of the GLP-1 RA?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Juan Frias, FACE, MD

Juan Frias, FACE, MD

Clinical Assistant Professor of Medicine University of California San Diego, California Chief Medical Officer National Research Institute Los Angeles, California